beovu
novartis europharm limited - brolucizumab - degenerarea maculară umedă - oftalmologice - beovu este indicat la adulți pentru tratamentul de forma neovasculară (umedă) degenerescenta maculara legata de varsta (amd).
jetrea
inceptua ab - ocriplasmin - boli retinale - oftalmologice - jetrea este indicat la adulți pentru tratamentul tractului vitreomacular (vmt), inclusiv atunci când este asociat cu gaura maculară cu diametru mai mic sau egal cu 400 microni.
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologice - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologice - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
yesafili
viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - oftalmologice - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.
trobalt
glaxo group limited - retigabina - epilepsie - antiepileptice, - trobalt este indicat ca tratament adjuvant de rezistente la medicamente convulsii parţiale-debut cu sau fara generalizare secundara la pacienţii în vârstă de 18 ani sau mai în vârstă cu epilepsie, în cazul în care alte combinaţii adecvate de droguri s-au dovedit inadecvate sau nu au fost tolerat.
visudyne
cheplapharm arzneimittel gmbh - verteporfina - myopia, degenerative; macular degeneration - oftalmologice - visudyne este indicat pentru tratamentul:adulți cu exudativa (umeda) degenerescenta maculara legata de varsta (amd), cu precădere clasic neovascularizație coroidiană subfoveală (cnv) sau;adulți cu neovascularizație coroidiană subfoveală secundară unei miopii patologice.
vabysmo
roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmologice - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologice - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
pegintron pulbere si solvent pentru solutie injectabila 100 mcg/0,5 ml
merck sharp&dohme limited - peginterferon alfa-2b - pulbere si solvent pentru solutie injectabila - 100 mcg/0,5 ml